BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Figure out How to Streamline Eco-friendliness in Your Volvo XC40 - 2How stripping diversity, equity and inclusion from health care may make Americans sicker
- 3Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- 4Zelensky warns of imminent massive Russian attack on Ukraine
- 5Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Building a Flourishing Business: Illustrations from Business people
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Make your choice for the PS5 game that you love playing with companions!
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Party Urban areas of the World
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- One month of war on Iran cost Arab countries up to $194bn: UNDP
